Table 1 Clinical and sociodemographic characteristics of the study subjects (n = 550) and their association with the DT score ≥ 4a
| Characteristic |
Overall N = 550 (%) |
DT cut off ≥ 4 N (%) |
DT cut off < 4 N (%) | P-value |
|---|---|---|---|---|
| Age in years | ||||
| Median (range) | 55 (18–85) | |||
| Mean ± SD | 51.37 ± 15.29 | 49.9 ± 14.86 | 52.62 ± 15.55 | < 0.001 |
| Gender | < 0.001 | |||
| Male | 224 (40) | 82 (37) | 142 (63) | |
| Female | 326 (60) | 172 (53) | 154 (47) | |
| Marital Status | 0.803 | |||
| Single | 66 (12) | 30 (45) | 36 (55) | |
| Married | 393 (72) | 178 (45) | 215 (55) | |
| Divorced | 16 (3) | 8 (50) | 8 (50) | |
| Widow | 75 (13) | 38 (51) | 37 (49) | |
| Educational level | 0.013 | |||
| Non-educated | 38 (7) | 25 (66) | 13 (34) | |
| Educated | 512 (93) | 229 (45) | 283 (55) | |
| Occupation | 0.820 | |||
| Student | 30 (5) | 14 (47) | 16 (53) | |
| No job | 371 (68) | 174 (47) | 197 (53) | |
| Job | 149 (27) | 66 (44) | 83 (56) | |
| Monthly Income (EP) | 0.484 | |||
| < 5000 | 305 (55) | 147 (48) | 158 (52) | |
| 5000–10,000 | 133 (24) | 63 (47) | 70 (53) | |
| 10,000–15,000 | 75 (14) | 30 (40) | 45 (60) | |
| > 15,000 | 37 (7) | 14 (38) | 23 (62) | |
| Health Insurance | 0.209 | |||
| Yes | 108 (20) | 44 (41) | 64 (59) | |
| No | 442 (80) | 208 (47) | 234 (53) | |
| Chronic disease | 0.055 | |||
| Present | 211 (38) | 107 (51) | 104 (49) | |
| Absent | 339 (62) | 147 (43) | 192 (57) | |
| Tumour Site | 0.006 | |||
| Head and Neck | 17 (3) | 10 (59) | 7 (41) | |
| Breast | 180 (33) | 93 (52) | 87 (48) | |
| Lung | 41 (8) | 24 (59) | 17 (41) | |
| GIT | 127 (23) | 56 (44) | 71 (56) | |
| Genitourinary | 71 (13) | 29 (41) | 42 (59) | |
| Musculoskeletal | 29 (5) | 6 (21) | 23 (79) | |
| Haematological | 85 (15) | 36 (42) | 49 (58) | |
| Type of malignancy | 0.486 | |||
| Hematological | 85 (15) | 36 (42) | 49 (58) | |
| Solid tumors | 465 (85) | 218 (47) | 247 (53) | |
| Stage | 0.001 | |||
| Stage 1 | 29 (5) | 6 (21) | 23 (79) | |
| Stage II | 108 (19) | 20 (19) | 88 (81) | |
| Stage III | 109 (20) | 24 (22) | 85 (78) | |
| Stage IV | 304 (56) | 204 (67) | 100 (33) | |